Holen Sie sich die Stockscreener-App
2.96
1.00%
-0.03
Handel nachbörslich:
2.96
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt AVXL?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$2.99
Offen:
$3.02
24-Stunden-Volumen:
998.95K
Relative Volume:
0.61
Marktkapitalisierung:
$274.31M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-39.95M
KGV:
-6.367
EPS:
-0.4649
Netto-Cashflow:
$-34.08M
1W Leistung:
+4.96%
1M Leistung:
-36.34%
6M Leistung:
-69.20%
1J Leistung:
-63.86%
1-Tages-Spanne:
$2.95
$3.09
1-Wochen-Bereich:
$2.85
$3.19
52-Wochen-Spanne:
$2.61
$13.99
Anavex Life Sciences Corporation Stock (AVXL) Company Profile
Firmenname
Anavex Life Sciences Corporation
Sektor
Branche
Telefon
844-689-3939
Adresse
630 5TH AVENUE, NEW YORK
Compare AVXL vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AVXL
Anavex Life Sciences Corporation
|
2.96 | 277.09M | 0 | -39.95M | -34.08M | -0.4649 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Anavex Life Sciences Corporation Stock (AVXL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-12-06 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-23 | Eingeleitet | Berenberg | Buy |
| 2021-09-23 | Eingeleitet | BTIG Research | Buy |
| 2020-12-16 | Bestätigt | H.C. Wainwright | Buy |
| 2020-09-28 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2020-02-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-06-18 | Eingeleitet | Janney | Buy |
| 2018-05-16 | Fortgesetzt | Maxim Group | Buy |
| 2018-03-08 | Eingeleitet | ROTH Capital | Buy |
| 2018-02-13 | Bestätigt | Maxim Group | Buy |
| 2017-09-29 | Fortgesetzt | Noble Financial | Buy |
| 2017-02-07 | Eingeleitet | Noble Financial | Buy |
| 2016-03-29 | Eingeleitet | FBR Capital | Outperform |
Alle ansehen
Anavex Life Sciences Corporation Aktie (AVXL) Neueste Nachrichten
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Anavex Life Sciences Corp. (AVXL) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Anavex Life Sciences Corp. (AVXL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
2026-04-05 | Anavex Life Sciences Corp. (AVXL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:AVXL | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Is Investigating Anavex Life Sciences Corp. (AVXL) And Encourages Investors to Connect - accessnewswire.com
Anavex Life Sciences Corp. (AVXL) stock price, news, quote and history - Yahoo Finance UK
2026-04-03 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Anavex Life Sciences Corp. (AVXL) And Encourages Investors to Connect | NDAQ:AVXL | Press Release - stockhouse.com
3 Promising Penny Stocks With At Least $200M Market Cap - Sahm
Bronstein, Gewirtz & Grossman, LLC Encourages Anavex Life Sciences Corp. (AVXL) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
AVXL Stock Price, Quote & Chart | ANAVEX LIFE SCIENCES CORP (NASDAQ:AVXL) - ChartMill
Anavex Life Sciences Corp (12X1.HM) Recent Insider Transactions - ca.finance.yahoo.com
AVXL Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Anavex Life Sciences' (AVXL) Buy Rating Reaffirmed at D. Boral Capital - marketbeat.com
Anavex Life Sciences Provides Comprehensive Regulatory Update - The Manila Times
After withdrawing its EU filing, Anavex keeps Alzheimer’s drug in talks - stocktitan.net
Bronstein, Gewirtz & Grossman, LLC Is Investigating Anavex Life Sciences Corp. (AVXL) And Encourages Stockholders to Connect - ACCESS Newswire
Anavex Life Sciences stock crushed as European Alzheimer's drug filing pulled after EMA pushback - MSN
2026-03-27 | Anavex Life Sciences Corp. (AVXL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | NDAQ:AVXL | Press Release - Stockhouse
Anavex Life Sciences Under Investigation for Securities Fraud - Intellectia AI
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp.AVXL - PR Newswire
Vanguard reports 0 AVXL shares after internal realignment (AVXL) - Stock Titan
Dow Surges Over 300 Points; Chewy Shares Jump On Upbeat Earnings - Sahm
Anavex Life Sciences Stock Crushed As European Alzheimer's Drug Filing Pulled After EMA Pushback - Sahm
Anavex Life Sciences Stock Is Deeply Oversold. Should You Buy the Dip? - Yahoo Finance
Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation - Yahoo Finance
Anavex asks EMA to re-examine its negative opinion on blarcamesine for Alzheimer's - MSN
AVXL Plummets 31% to 52-Week Lows: A Technical Meltdown Ignites the Biotech Watchlist - Bitget
Anavex Life Sciences withdraws EU marketing application for blarcamesine after CHMP feedback - TradingView
Anavex (NASDAQ: AVXL) withdraws EU Alzheimer’s drug application for blarcamesine - Stock Titan
Crude Oil Moves Lower; Cintas Raises FY2026 Forecast - Benzinga
Anavex Life Sciences Corp Faces Competitive Pressure Amid Financial Year Results - StocksToTrade
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer's Disease - Bitget
Anavex Life Sciences Corp. (AVXL) recently disclosed the latest updates on the regulatory review of its investigational drug Blarcamesine for early Alzheimer’s disease in the European Union. - Bitget
Anavex Life Sciences provides update on regulatory review in the EU for blarcamesine to treat early Alzheimer's disease - marketscreener.com
Anavex Life Sciences stock tumbles after EU filing withdrawal By Investing.com - Investing.com Australia
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease - The Manila Times
Anavex Life Sciences stock tumbles after EU filing withdrawal - Investing.com
EU review halts Anavex’s Alzheimer’s drug bid, more data next - Stock Titan
Anavex Life lead drug targets early Alzheimer's causenew study highlights - MSN
AVXL Stock Soars After Anavex’s New Data Suggests Its Alzheimer’s Drug May Slow Brain Shrinkage - Stocktwits
D. Boral Capital Reiterates Buy Rating for Anavex Life Sciences (NASDAQ:AVXL) - MarketBeat
Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease - The Manila Times
Study ties oral Alzheimer’s drug to slower brain shrinkage - Stock Titan
Anavex Life Lead Drug Targets Early Alzheimer's CauseNew Study Highlights - Sahm
Form 8K Anavex Life Sciences Corp For: 9 February - Investing.com
Anavex Life Sciences Announces New Study Linking Autophagy Dysfunction to Alzheimer’s Disease Pathology - Quiver Quantitative
New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease - The Manila Times
Alzheimer’s study points to cell-cleanup failure before plaques form - Stock Titan
Finanzdaten der Anavex Life Sciences Corporation-Aktie (AVXL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Anavex Life Sciences Corporation-Aktie (AVXL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Thomas Steffen | Director |
Jun 05 '25 |
Option Exercise |
1.76 |
50,000 |
88,000 |
55,000 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):